Chinese CRO R&G buys into Medidata's trial tech

R&G Pharma Studies, a Chinese CRO, is deepening its relationship with clinical trial tech provider Medidata ($MDSO), adopting the company's cloud-based management system.

Headquartered in Beijing, R&G is buying into Medidata's clinical trial management system, or CTMS, becoming the first Chinese company to do so. Medidata bills its CTMS as an all-in-one offering that allows CROs and sponsors to manage trial sites, monitor results and dole out payments from anywhere in the world.

R&G first reached out to Medidata last year, adopting the firm's technology for electronic data capture and management, and the CRO's latest move gives Medidata a chance to expand the use of its banner products, the company said.

"China is a key market in (Asia Pacific's) expanding clinical trial landscape, and R&G is well positioned to support clinical innovation in the region," Medidata Vice President Edwin Ng said in a statement. "By pairing Medidata's agile, cloud-based technology with R&G's deep clinical expertise and industry insight, we look forward to fueling better, more strategic research across the region."

R&G is now among the roughly two-thirds of Medidata customers that use two or more of the company's products. In 2014, that number was below 60%, Medidata said.

- read the statement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.